stockportfolio.pro
Mirion Technologies, Inc. (MIR)
Industrials · Specialty Industrial Machinery · NYSE
Mirion Technologies, Inc. revenue & earnings — last 10 fiscal years
| Metric | 2019 | 2019 | 2020 | 2020 | 2021 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $440.10M | $0 | $478.20M | $0 | $611.60M | $0 | $717.80M | $800.90M | $860.80M | $925.40M |
| Gross profit | $188.20M | — | $197.00M | — | $251.80M | — | $310.10M | $356.40M | $399.70M | $438.60M |
| Net income | $-122.00M | $-341 | $-119.10M | $-45.26M | $-158.30M | $-158.40M | $-276.90M | $-96.90M | $-36.20M | $28.80M |
| Net margin | -27.7% | — | -24.9% | — | -25.9% | — | -38.6% | -12.1% | -4.2% | 3.1% |
Source: Mirion Technologies, Inc. SEC filings (10-K). 11 years of history available in the interactive view.
Explore 11 years of Mirion Technologies, Inc. financials — interactive
Full income statement, balance sheet and cash flow with CAGR and trend on every row, 48 quarters, valuation ratios, plain-English health checks, and Ask — our SEC-grounded research assistant.
Open the interactive view — freeOr start a 7-day free trial to track MIR in your portfolio →
About Mirion Technologies, Inc.
Mirion Technologies, Inc. provides radiation detection, measurement, analysis, and monitoring products and services in North America, Europe, and the Asia Pacific. It operates in two segments, Medical, and Nuclear & Safety. The Medical segment offers radiation oncology quality assurance and dosimetry solutions; patient safety solutions for diagnostic imaging and radiation therapy centers; radiation therapy quality assurance solutions for calibrating and verifying imaging and treatment accuracy; and radionuclide therapy products for nuclear medicine applications, such as product handling, medical imaging furniture, and rehabilitation products. This segment improves the quality and safety of cancer care delivery; and supports applications across medical diagnostics and practitioner safety. The Nuclear & Safety segment focuses on addressing critical radiation safety, measurement, and analysis applications; and provides personal radiation detection, identification equipment, and analysis tools. The company also offers include radiation measurement and monitoring solutions, reactor instrumentation and control detectors, imaging systems and cameras, and waste management systems; laboratory and scientific analysis systems comprising gamma/alpha spectroscopy, alpha/beta counting, specialty detectors, and spectroscopy software; radiation measurement and health physics instrumentation; and contamination and clearance monitors. It serves hospitals, clinics and urgent care facilities, dental and veterinary offices, radiation treatment facilities, OEMs for radiation therapy, laboratories, military organizations, government agencies, industrial companies, power and utility companies, reactor design firms, and NPPs. The company was formerly known as Global Monitoring Systems, Inc. and changed its name to Mirion Technologies, Inc. in January 2006. Mirion Technologies, Inc. was incorporated in 2005 and is headquartered in Atlanta, Georgia.
Mirion Technologies, Inc. — frequently asked questions
What is Mirion Technologies, Inc.'s revenue?
Mirion Technologies, Inc. (MIR) reported revenue of $925.40M for fiscal year 2025, up 7.5% from the prior year, according to its SEC filings.
Is Mirion Technologies, Inc. profitable?
Yes. MIR earned net income of $28.80M in fiscal 2025, a net margin of 3.1%.
What is MIR's P/E ratio?
Mirion Technologies, Inc. trades at a price-to-earnings ratio of about 157.7 based on the latest data in our nightly-refreshed cache.
How fast is Mirion Technologies, Inc. growing?
MIR's revenue grew at roughly 8.6% per year over the last five fiscal years (compound annual growth rate), computed from SEC-filed statements.
Where does this data come from?
All figures are computed from Mirion Technologies, Inc.'s official SEC filings (10-K and 10-Q), covering 11 years of history, refreshed nightly. stockportfolio.pro does not provide investment advice.